frequencies from limiting dilution assays were determined using the Extreme Limiting Dilution Assay (ELDA) software tool 26 .
Expression profiling of Eμ-myc and Eμ-myc/Suz12
Plt8/+ lymphomas Total RNA from seven Eμ-myc/Suz12 +/+ and five Eμ-myc/Suz12 Plt8/+ FACS-purified lymphomas were sequenced at the Australia Genome Research Facility. An average of 12.2 million single-end 100bp sequence reads were obtained per lymphoma sample on an Illumina GA-II Sequencer. An average of 95% of the reads were successfully mapped to the mm9 mouse genome build using the Bioconductor package Rsubread
27
. The RNA-Seq profiles were summarized using the feature Counts function to count the number of reads overlapping the exome of each gene. Differential expression analysis was performed using the Bioconductor package edgeR 28 . Reads mapping to immunoglobulin, ribosomal RNA and mitochondrial protein genes were filtered out of the analysis.
Genes on the X-and Y-chromosomes were also removed to avoid any confounding factors due to lymphomas arising from mice of different sexes. Read counts were TMM normalised 29 to adjust for compositional differences between samples. Genewise estimates of biological variation were obtained using empirical Bayes moderated dispersions 30 . Statistical significance was assessed using an exact test for negative binomial distributed data 31 . To prepare for gene set testing, the read counts were transformed to approximately standard normal deviates using the zscoreNBinom function of the edgeR package. A battery of gene sets from the Broad Institute's curated C2 molecular signatures database 32 was tested using the CAMERA function of the limma package 33 .
This is a competitive gene set test which tests whether the genes in the gene set are significantly more up-or down-regulated compared to the other genes in the experiment. Human gene symbols were mapped to mouse orthologs using the Mouse Genome Database 34 .
RESULTS

Suz12 Plt8/+ mice have elevated numbers of B-lymphocytes
Previous studies have demonstrated that mice carrying a heterozygous loss-of-function allele of Suz12, Ezh2 or Eed have enhanced hematopoietic stem cell activity and platelet production 9,24,35 .
However, the impact of these mutations has not been detailed in other hematopoietic cells types.
Using Suz12 Plt8/+ mice to model hypomorphic PRC2 function, we found a consistent elevation in blood leukocytes relative to Suz12 +/+ mice at both 4 and 8 weeks of age (Figure 1 ), which was exclusively due to higher lymphocyte counts (Tables S1, S2 ).
Progenitor cell analysis in Suz12
Plt8/+ mice
The elevated numbers of B cells in Suz12
Plt8/+ mice prompted us to examine B cell development in detail at 4 and 8 weeks of age. The numbers of cells at various stages of B-lymphoid maturation appeared unaltered at both ages, although a modest increase in total B-lymphoid cell numbers was evident in 8-week-old Suz12 Plt8/+ mice (Figures 2A,B and Tables S3, S4 ). Enumeration of B-and Tcell subsets in the spleen and thymus of Suz12 Plt8/+ mice revealed no significant abnormalities (Tables S3, S4 ). There was a modest increase in the number of LSK cells and multi-potent progenitors (MPPs) in Suz12 Plt8/+ mice at weaning ( Figure 2D ), although this was less pronounced in adult mice (Table S3) . Enumeration of lymphoid-primed multi-potent progenitors (LMPPs), and common lymphoid progenitors (CLPs) did not reveal significant differences between Suz12 Plt8/+ and Suz12 +/+ mice. Similarly, sub-fractionation of the CLP population into ALPs (Ly6D -; all-lymphoid progenitors) and BLPs (Ly6D + ; B-cell primed progenitors) 36 did not reveal any changes in
Suz12
Plt8/+ mice ( Figure 2C ,D and Table S3 ). To determine whether impaired PRC2 function influenced the expression of the master B-cell regulators Pax5, Ebf1 and E2A in immature progenitors, as observed in Bmi1-knockout mice 37 , we compared their expression in purified HSC, MPP, LMPP and CLP populations. There were no significant differences in the relative expression of these genes in all populations examined between Suz12 +/+ and Suz12 Plt8/+ mice ( Figure S1 ).
Suz12 deficiency results in increased clonogenicity of B-lymphoid progenitors
The frequency (f) of B-lymphoid progenitors with proliferative potential was assessed by limiting dilution from unfractionated bone marrow cells. Suz12 Plt8/+ mice contained a higher number of clonogenic progenitors than Suz12 +/+ controls ( Figure 3A ). This observation was independently verified when equal numbers of bone marrow cells from 3-week-old Suz12 +/+ and Suz12 Plt8/+ mice were cultured in methylcellulose for development of B-lymphoid colonies ( Figure 3B Figure 3D ). Increased re-plating potential of
Suz12
Plt8/+ pro-B cells was confirmed in a separate experiment in which 20 individual colonies from primary cultures were re-plated individually into secondary cultures. The frequency and the absolute number of secondary colonies were significantly higher in Suz12 Plt8/+ pro-B cells than control ( Figure 3E ).
There was a modest decrease in global H3K27me3 level in Suz12 Plt8/+ pro-B cells compared to
+/+ pro-B cells, which coincided with a slight decrease in Suz12 and Ezh2 levels ( Figure S2A ).
This effect was more pronounced in pro-B cells expressing shRNA to Suz12, in which a profound reduction in Suz12, Ezh2 and global H3K27me3 levels was evident ( Figure S2B ). The level of H2AK119ub, the histone mark deposited by PRC1, was not altered in Suz12-deficient cells relative to total protein ( Figure S2 ). Figure 4A ). In contrast, Eμ-myc/Suz12 Plt8/+ mice showed accelerated onset of disease with a median survival of 72 days ( Figure 4A ). This suggests that unlike Bmi1, which promotes lymphomagenesis in Eμ-myc mice, Suz12 functions as a tumor suppressor.
PRC2 restricts Eμ-myc lymphomagenesis
Analysis of moribund Eμ-myc/Suz12
Plt8/+ mice revealed lymphomas typical of those observed in Eμ-myc/Suz12 +/+ mice. All moribund mice presented with lymphadenopathy, splenomegaly ( Figure   S3A ) and increased leukocyte numbers, accompanied by normal red blood cell counts and mild thrombocytopenia ( Figure S3D-F) . All lymphomas were of B-lymphoid origin, and the proportion of pre-B, sIg + B or mixed pre-B/mature B lymphomas were consistent ( Figure S3B ). To verify malignancy, 2 x 10 6 splenocytes from lymphoma-bearing mice were transplanted into nonirradiated recipients. As documented for Eμ-myc disease 39 , lymphomas developed quickly in all recipients, but the disease latency did not differ between recipients of Eμ-myc/Suz12 +/+ and Eμ-
myc/Suz12
Plt8/+ lymphomas ( Figure S3C ). Eμ-myc/Suz12 Plt8/+ lymphomas displayed a variable but on average modest reduction in Suz12 levels compared to Eμ-myc lymphomas, while there was no consistent difference in Ezh2 levels ( Figures 4B and S2C ). Global H3K27me3 levels varied considerably between individual Eμ-myc/Suz12 +/+ lymphomas, and a similar pattern was observed in Eμ-myc/Suz12 Plt8/+ lymphomas, with no consistent differences between the two groups.
To independently confirm that reduced PRC2 activity accelerates Eμ-myc lymphoma, E13.5 
Expanded B-lymphopoiesis in pre-neoplastic Eμ-myc/Suz12
To understand the mechanisms behind accelerated lymphoma onset, we examined changes in cellular pathways in pre-neoplastic mice, a distinct phase in 3-4 week-old mice defined by the lack of transplantable tumor cells 40 . Lymphomas failed to develop in mice transplanted with 10 also exists in these mice. Quantitative RT-PCR analysis from purified bone marrow pre-B cells
showed that the Suz12 Plt8 mutation did not influence c-myc RNA levels ( Figure S6 ), excluding the possibility that accelerated lymphomagenesis in Eμ-myc/Suz12 Plt8/+ mice was simply due to increased transgene expression.
Pre-neoplastic Eμ-myc/Suz12
Plt8/+ mice exhibited a 3-fold increase in blood leukocytes relative to control mice ( Figure 5A ), primarily due to increased lymphocytes (Table S2 ). In contrast, Eμ-myc/Bmi1 +/-mice showed significant reduction in total leukocytes (Figures 5A) and lymphocytes (Table S2 ). Analysis of nucleated blood cells revealed a marked increase in total B-lymphoid cell numbers in Eμ-myc/Suz12 Plt8/+ mice relative to Eμ-myc littermates, while a significant reduction in B-lymphoid cells was observed in Eμ-myc/Bmi1 +/-mice ( Figure 5B ). While bone marrow cellularity was constant in the three groups (Table S4) , Eμ-myc/Suz12 Plt8/+ mice had increased number of B-lineage cells compared to Eμ-myc mice, due to elevated numbers of sIg -precursors ( Figure 5C and Table S4 ). In contrast, Eμ-myc/Bmi1 +/-mice had fewer B-lymphoid cells than in Eμ-myc controls ( Figure 5C and Table S4 ). Eμ-myc mice exhibited significant splenomegaly, both in weight and cellularity, which was further exacerbated in Eμ-myc/Suz12 Plt8/+ mice, while the opposite was observed in Eμ-myc/Bmi1 +/-mice (Table S4 ). This was attributable to an increased number of total splenic B-lymphoid cells and specific subsets including pre-B, immature and mature B cells ( Figure 5D ). The numbers of T lymphocytes and myeloid cells were generally within the normal range in mice of all genotypes (Table S4) .
Suz12 deficiency has no influence on apoptosis or cell cycle of Eμ-myc B-lymphoid cells
Pre-neoplastic Eμ-myc/Suz12 Plt8/+ mice had an increased frequency of B-cell progenitors in their 
Gene expression analysis of PRC2-deficient lymphomas
A gene-level differential expression analysis revealed 35 genes up-regulated (Table S5 ) and 32 genes down-regulated ( . These studies collectively
show that maintenance of PRC2 activity within a defined normal range is essential, as either reduced or excess activity predisposes to malignancy. Modulation of epigenetic regulators, including EZH2, is an exciting and rapidly developing area in cancer therapy 48, 49 . It is important to consider that PRC2 is clearly acting as a tumor suppressor in some contexts, which has important implications for how to approach this complex therapeutically. 
